KR20240117164A - 피부 질환의 치료를 위한 미생물 조성물 - Google Patents

피부 질환의 치료를 위한 미생물 조성물 Download PDF

Info

Publication number
KR20240117164A
KR20240117164A KR1020247018262A KR20247018262A KR20240117164A KR 20240117164 A KR20240117164 A KR 20240117164A KR 1020247018262 A KR1020247018262 A KR 1020247018262A KR 20247018262 A KR20247018262 A KR 20247018262A KR 20240117164 A KR20240117164 A KR 20240117164A
Authority
KR
South Korea
Prior art keywords
composition
strain
seq
sequence
bacterial strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018262A
Other languages
English (en)
Korean (ko)
Inventor
자레드 케헤
베르나르도 세르반테스
체리 애커먼
압둘라만 하사발라
키튼 아르멘트라우트
Original Assignee
콘체르토 바이오사이언시스, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘체르토 바이오사이언시스, 아이엔씨. filed Critical 콘체르토 바이오사이언시스, 아이엔씨.
Publication of KR20240117164A publication Critical patent/KR20240117164A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247018262A 2021-11-11 2022-11-10 피부 질환의 치료를 위한 미생물 조성물 Pending KR20240117164A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278134P 2021-11-11 2021-11-11
US63/278,134 2021-11-11
PCT/US2022/079637 WO2023086883A1 (en) 2021-11-11 2022-11-10 Microbial compositions for the treatment of skin diseases

Publications (1)

Publication Number Publication Date
KR20240117164A true KR20240117164A (ko) 2024-07-31

Family

ID=86336611

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018262A Pending KR20240117164A (ko) 2021-11-11 2022-11-10 피부 질환의 치료를 위한 미생물 조성물

Country Status (8)

Country Link
US (3) US12115197B2 (https=)
EP (1) EP4429683A1 (https=)
JP (1) JP2024544960A (https=)
KR (1) KR20240117164A (https=)
CN (1) CN118541163A (https=)
AU (1) AU2022388745A1 (https=)
CA (1) CA3237750A1 (https=)
WO (1) WO2023086883A1 (https=)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660645C (en) 2006-08-11 2016-04-05 Novozymes Biologicals, Inc. Bacillus cultures for use in washing, cleaning, stain removal, or degrading waste materials
KR100878799B1 (ko) * 2007-03-13 2009-01-14 한국생명공학연구원 항생제 내성 병원성 미생물 또는 장내 유해 미생물의생장을 억제하는 바실러스 아밀로리퀴페시언스 ｋ317
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US20160073642A1 (en) 2013-05-03 2016-03-17 Universidad Eafit Production process for biomass and fengycin metabolites of bacillus species and compositions thereof for biological pest control
US20180289751A1 (en) * 2015-05-05 2018-10-11 The Regents Of The University Of California Antimicrobial therapy
WO2018049182A2 (en) 2016-09-08 2018-03-15 Locus Solutions, Llc Distributed systems for the efficient production and use of microbe-based compositions
KR20190140063A (ko) 2017-05-07 2019-12-18 로커스 아이피 컴퍼니 엘엘씨 피부 건강을 위한 화장품 조성물 및 이를 사용하는 방법
EP3784807B1 (en) 2018-04-23 2025-06-04 Evonik Operations GmbH Synbiotic compositions
US20220096574A1 (en) 2019-01-29 2022-03-31 Holobiome, Inc. Methods and compositions for treating and preventing central nervous system disorders and other conditions caused by gut microbial dysbiosis
JP7689077B2 (ja) 2019-02-11 2025-06-05 エボニック オペレーションズ ゲーエムベーハー バシラエン産生細菌またはその調製物を含有する組成物
MX2021012558A (es) * 2019-04-17 2022-01-04 Andes Ag Inc Metodos innovadores para el tratamiento de las semillas y componentes para mejorar los atributos y el rendimiento de la planta.
BR112021023020A2 (pt) 2019-05-20 2022-01-04 Evonik Operations Gmbh Uso de ésteres de poliglicerol como carreador para ingredientes microbiológicos ativos
MX2021015725A (es) 2019-06-19 2022-04-01 Basf Corp Formulaciones agroquimicas acuosas que comprenden esporas de bacterias.
GB201911925D0 (en) 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
CA3187427A1 (en) 2020-06-17 2021-12-23 Bioconsortia, Inc. Agriculturally beneficial microbes, microbial compositions, and consortia
EP4223301A1 (en) 2020-09-07 2023-08-09 Il Dong Pharmaceutical Co., Ltd. Composition for preventing or treating periodontal diseases, comprising bacillus velezensis strain, culture medium thereof, or culture supernatant thereof as active ingredient
JP2023543355A (ja) 2020-09-25 2023-10-13 バイオームエディット・エルエルシー プロバイオティックバチルス属組成物及び使用方法
WO2022119895A1 (en) 2020-12-01 2022-06-09 Dupont Us Holding, Llc Methods and compositions for microbial treatment of skin disorders
IL305939A (en) 2021-03-14 2023-11-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Bacillus antibacterial agents
WO2022226376A2 (en) 2021-04-22 2022-10-27 Indigo Ag, Inc. Endophyte compositions and methods for improved plant health
WO2023091342A1 (en) 2021-11-16 2023-05-25 Phibro Animal Health Corporation Preservation system for stabilizing spore-forming microbials

Also Published As

Publication number Publication date
US12329787B2 (en) 2025-06-17
WO2023086883A1 (en) 2023-05-19
US20240424033A1 (en) 2024-12-26
AU2022388745A1 (en) 2024-05-30
JP2024544960A (ja) 2024-12-05
US12115197B2 (en) 2024-10-15
CA3237750A1 (en) 2023-05-19
US20250268955A1 (en) 2025-08-28
US20240189369A1 (en) 2024-06-13
EP4429683A1 (en) 2024-09-18
CN118541163A (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
US11590092B2 (en) Skin probiotic
Hendricks et al. Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends
Barbour et al. Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome
WO2019050898A1 (en) METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY SKIN DISEASE
Oh et al. The human skin microbiome: from metagenomes to therapeutics
Al-Awadi et al. Antibacterial and therapeutic effects of vancomycin-resistant Staphylococcus aureus bacteriocin (VRSAcin) in the treatment of VRSA skin infection in mice
WO2024125471A1 (zh) 用于改善或维持哺乳动物皮肤健康的方法和组合物
Cui et al. Metagenomic insights into the effects of cosmetics containing complex polysaccharides on the composition of skin microbiota in females
KR20240117164A (ko) 피부 질환의 치료를 위한 미생물 조성물
KR102264354B1 (ko) 피부 상태 개선용 조성물
Kao et al. The mPEG-PCL copolymer for selective fermentation of Staphylococcus lugdunensis against Candida parapsilosis in the human microbiome
Kush et al. Evaluation of antimicrobial action of Carie Care™ and Papacarie Duo™ on Aggregatibacter actinomycetemcomitans a major periodontal pathogen using polymerase chain reaction
Kim et al. Distinct Cutibacterium acnes subspecies defendens strains classified by multi-omics dissection alleviate inflammatory skin lesions of a rosacea-like mouse model
KR102544440B1 (ko) 피부 상재균으로부터 유래된 엔테로박터 에어로게네스 j2k-739 균주 및 피부 상재균 유래 엔테로박터속을 자극원으로 처리하는 신규한 항주름평가 방법
EP4527399A1 (en) Composition for treating ringworm
Hooper et al. 522 Skin microbiome in cutaneous T-cell lymphoma is associated with phototherapy treatment response
WO2024063132A1 (ja) 抗菌組成物および該抗菌組成物の対象への投与を判定する方法
Hu et al. Dual probiotic intervention with Lactiplantibacillus plantarum Kmiate-6 and Pediococcus acidilactici Kmiate-15 improves periodontal health and oral microbiota balance in dogs
Hong et al. 444 The regulation of autophagy and AhR in Langerahans cells in the decreased inflammation of imiquimoid-induced psoriasis
Mur et al. 446 Impact of skin microbiota on the composition and properties of botanical extract
Tong et al. The human skin microbiome.
Park et al. Inhibitory effects of oral probiotics on biofilm formation, growth, and filament development in Candida albicans
Meyrignac et al. 521 Development of 3D reconstructed skin models with PBMC-derived immune cells
Nakatsuji et al. 525 How the inappropriate innate immune response of atopic dermatitis promotes dysbiosis of the skin microbiome
HK40121821A (zh) 白癣治疗用组合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000